Integrated Research Limited (ASX:IRI)
Australia
· Delayed Price · Currency is AUD | Market Cap | 53.27M |
| Revenue (ttm) | 67.76M |
| Net Income (ttm) | 7.26M |
| Shares Out | 180.59M |
| EPS (ttm) | 0.04 |
| PE Ratio | 7.30 |
| Forward PE | 42.14 |
| Dividend | 0.02 (6.72%) |
| Ex-Dividend Date | Sep 3, 2025 |
| Volume | 56,881 |
| Average Volume | 67,591 |
| Open | 0.295 |
| Previous Close | 0.298 |
| Day's Range | 0.295 - 0.300 |
| 52-Week Range | 0.270 - 0.510 |
| Beta | 1.57 |
| RSI | 42.80 |
| Earnings Date | May 27, 2026 |
About Integrated Research
Integrated Research Limited designs, develops, implements, and sells software for business-critical computing, unified communication, and payment networks. The company offers Prognosis, an integrated suite of monitoring and management software designed to give an organization’s management and technical personnel operational insight into the HP NonStop platform, distributed system servers, unified communications, payment environments, and business applications. It also provides licensing, testing, maintenance, and professional services, as well ... [Read more]
Financial Performance
In fiscal year 2025, Integrated Research's revenue was 68.26 million, a decrease of -18.05% compared to the previous year's 83.29 million. Earnings were 13.36 million, a decrease of -50.76%.
Financial StatementsNews
Integrated Research Earnings Call Transcript: H1 2026
Revenue and earnings declined due to a softer renewals book and a large credit loss, but cash and net assets remain strong. Product-led growth advanced with new AI and SaaS offerings, and management is prioritizing investment in innovation over buybacks.
Integrated Research Transcript: AGM 2025
The meeting highlighted disciplined financial management, a robust balance sheet, and a continued focus on product-led growth. New products like Prognosis Elevate and Iris were launched, with further innovation and medium-term growth expected as new offerings roll out in 2026.
Integrated Research Earnings Call Transcript: H2 2025
FY 2025 saw revenue and profit declines due to lower renewals and expansion revenue, but new client revenue and product innovation showed early promise. Significant investment in product-led growth and AI is expected to dampen profits for two to three years as the company transitions to a more sustainable growth model.
Integrated Research Earnings Call Transcript: H1 2025
New business revenue surged 76% year-over-year, offsetting some impact from a 36% drop in total contract value due to soft renewals. Pro forma revenue was stable, and a new High Value Payments product was launched with a major US bank as a client.
Integrated Research Transcript: AGM 2024
The meeting highlighted a strong financial turnaround, with significant revenue and profit growth, a refreshed board, and a focus on product-led innovation. Strategic priorities include new product development, disciplined capital management, and targeted sales improvements, while maintaining a prudent dividend policy.
Integrated Research Earnings Call Transcript: H2 2024
FY 2024 saw 19% revenue growth, strong cash generation, and a turnaround in the Americas, despite ongoing churn in Collaborate. FY 2025 will focus on larger enterprise customers, product-led growth, and balanced capital allocation, with churn and market shifts remaining key risks.